611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
Live Near a 'Superfund' Site? Your Life Span Might Be ShorterHormone Treatments May Raise Blood Pressure in Transgender PeopleUnexplained Drop in Resting Heart Rate in Youth 'Not a Good Thing'Common MS Meds Might Be Less Effective in Black PatientsIs It Allergies or COVID? Expert Shows How to Tell the DifferenceMany Employees Have Mixed Feelings as Offices ReopenHalf of American Adults Have Now Gotten at Least One COVID Vaccine ShotWarmer Climate, More Pollen, Worse Allergies: How to Fight BackCycling During Dialysis? It Might Help PatientsPregnancy Raises the Risk for Kidney StonesU.S. Marines Study Finds Getting COVID Won't Protect Young People From ReinfectionKnow the Signs of Rare Blood Clot Linked With J & J Vaccine1 in 50 COVID Patients in ICU Will Develop a StrokeBooster Shots a Likely Reality for COVID-Vaccinated AmericansAHA News: The Link Between Structural Racism, High Blood Pressure and Black People's HealthMost Young Americans Eager to Get COVID Vaccine: PollRashes Can Occur After COVID Vaccine,  But Dermatologists Say 'Don't Worry'Even Before COVID, Many More People Died Early in U.S. Versus EuropeCOVID Plus 'Bleeding' Stroke Doubles a Patient's Death RiskLower Rates of COVID in States That Mandated Masks: StudyCDC Panel Says It Needs More Time to Study J&J Vaccine Clotting CasesOne Good Way to Help Beat COVID: ExerciseDiabetes Can Lead to Amputations, But Stem Cell Treatment Offers HopeResearch Shows Links Between Gum Disease and Alzheimer'sNo Rise in Global Suicide Rate in First Months of PandemicCloth Masks Do Make Workouts a Bit Tougher, Study FindsMany Kids Who Develop Severe COVID-Linked Syndrome Have Neurologic SymptomsBiden, Fauci Say Pause in J&J COVID Vaccine Is Sign That Safety Comes FirstAHA News: Straight Answers to Common Questions About COVID-19 VaccinesJ&J Vaccine 'Pause' Is Not Mandate Against the Shot, FDA SaysU.K. Variant Won't Trigger More Severe COVID, Studies FindNewborns Won't Get COVID Through Infected Mom's Breast Milk: StudyU.S. Health Agencies Call for Pause in J&J COVID Vaccine After 6 People Develop ClotsUrinary Incontinence Surgery Won't Raise a Woman's Cancer RiskCOVID Vaccines Trigger Protective Immune Response in Nursing Home Residents: StudyCOVID Vaccines Might Not Protect Certain Cancer PatientsHad Facial Fillers? What You Need to Know About COVID VaccinesAntibody Cocktail May Curb Infection in Unvaccinated Who Are Exposed to COVID-19Scientists Find Clues to Why AstraZeneca's Vaccine May Cause ClotsYou've Got Fungi in Your Lungs, and That's OKNon-Emergency Surgeries Are Rebounding, But Backlogs RemainPandemic Has Put Many Clinical Trials on HoldSupply of J&J COVID Vaccine to Drop 86 Percent Next WeekStressed, Exhausted: Frontline Workers Faced Big Mental Strain in PandemicNIH Starts Trial Looking at Rare Allergic Reactions to COVID VaccinesNot Just Keyboards: Many Types of Workers Can Develop Carpal TunnelBlack Women Are Dying of COVID at Much Higher Rates Than White MenTwo Vaccines Show Effectiveness Against Emerging COVID VariantsWomen More Prone to Concussion's Long-Term Harms: StudyCOVID Cases Climb in the Midwest as British Variant Takes Hold in U.S.
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

NIH Halts Trial of Convalescent Plasma for Mild COVID-19

HealthDay News
by Robert Preidt
Updated: Mar 3rd 2021

new article illustration

WEDNESDAY, March 3, 2021 (HealthDay News) -- A clinical trial evaluating the use of convalescent plasma in patients with mild to moderate COVID-19 symptoms has been halted because the treatment didn't benefit them, according to the U.S. National Institutes of Health.

Convalescent plasma (also called "survivor's plasma") is derived from the blood of patients who have already recovered from COVID-19. It's thought that infusions of the antibody-rich plasma might give patients an extra weapon to fight off SARS-CoV-2.

The NIH study included patients seen at an emergency department who's had mild to moderate coronavirus symptoms for a week or less.

However, "even if enrollment continued, this trial was highly unlikely to demonstrate that COVID-19 convalescent plasma prevents progression from mild to severe illness" in at-risk patients who seek emergency care but are not hospitalized, an NIH news release said.

The trial to assess the safety and effectiveness of the therapy began in August and included 47 emergency departments nationwide. Of the 900 adult patients it sought to recruit, 511 were enrolled before the trial was halted. Patients had at least one risk factor associated with severe COVID, such as obesity, high blood pressure, diabetes, heart disease or chronic lung disease. But when they arrived at the ER, none were sick enough to be hospitalized.

Study participants received either convalescent plasma or a placebo. They were then followed to assess three outcomes: If they sought further emergency or urgent care, if they had to be hospitalized, or if they died within 15 days of entering the trial.

While the study found the treatment to be safe, the researchers found no significant differences in the three outcomes between those who received the COVID-19 convalescent plasma or the placebo.

An independent monitoring board recommended halting the trial after a Feb. 25 meeting, and the study stopped enrolling new patients.

Based on earlier studies that suggested convalescent plasma might be of benefit, more than 100,000 people in the United States and many more worldwide have been given the therapy since the pandemic began.

The findings contrast with a small Argentinian study of 160 elderly patients who were infected but not yet sick enough to be hospitalized. That study, published in January in the New England Journal of Medicine, concluded that convalescent plasma could help prevent severe illness in older patients who were newly infected with coronavirus.

Researchers in that study said two factors were key: Donor plasma had to be given within 72 hours of the start of symptoms, and the plasma must have a high concentration of antibodies.

More information

The U.S. Centers for Disease Control and Prevention has more on COVID-19.

SOURCE: U.S. National Institutes of Health, news release, March 2, 2021